Medication info
TelmidiFin Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

TelmidiFin Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202500518 · Approved 2025.03.07 · Insurance code 657808370

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; it may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • stroke risk
  • myocardial infarction risk
  • vascular revascularization risk
View approved original text

This medication is used for patients with essential hypertension that is not controlled by monotherapy with telmisartan and amlodipine, and is suitable for patients who must take rosuvastatin simultaneously. The telmisartan/amlodipine combination is effective in controlling blood pressure in patients with essential hypertension. Rosuvastatin is used as an adjunctive treatment in patients with primary hypercholesterolemia and mixed hyperlipidemia that is not controlled by diet and exercise. It also helps manage lipid levels in patients with homozygous familial hypercholesterolemia and primary dysbetalipoproteinemia. This medication reduces total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis and contributing to the reduction of stroke, myocardial infarction, and vascular revascularization risks in patients with chronic cardiovascular disease risk factors. Therefore, it is very useful in the treatment of patients who require both blood pressure and lipid management.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; it may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any components of this drug or similar components, or those with specific liver, kidney diseases, or severe muscle disorders, should avoid taking this medication. Particular caution is necessary for patients with severely impaired kidney function or those with specific drug interactions due to increased risk of side effects. Elderly individuals, patients with low blood pressure, and patients with compromised liver function should use this medication with extra caution, and regular blood tests and health checks are recommended. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur, the physician should be consulted immediately, and blood tests may be required to check for muscle damage. This medication may affect liver function, so liver enzyme levels should be monitored regularly, and the drug should be discontinued if liver function deteriorates significantly. While taking this medication, there is a possibility of drug interactions; therefore, all medications being taken should be disclosed to healthcare professionals and closely monitored. Caution is advised when driving or operating heavy machinery due to the risk of dizziness or drowsiness. Women of childbearing potential should employ appropriate contraception while taking this medication, and it is advisable not to take it during breastfeeding. This medication is not recommended for children under 18 years old, and elderly patients should start with a lower dose and gradually adjust the dosage. In case of overdose, symptoms such as low blood pressure, dizziness, and heart problems may occur; if these symptoms appear, immediate medical attention is required. This medication should be kept out of reach of children, and transferring it to another container is not advisable as it may compromise quality.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like syndrome, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina, rapid pulse, leg edema, insomnia, drowsiness, migraine, vertigo, sensory disturbances, involuntary muscle contractions, erectile dysfunction, increased sweating, flushing, allergies, fever, leg pain, lethargy, palpitations, vascular edema, vasculitis, peripheral neuropathy, trembling, appetite loss, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, weakness, burning sensation, stiffness, weight gain, weight loss, sexual dysfunction, nervousness, depression, abnormal dreams, anxiety, depersonalization, vascular edema, erythema multiforme, pruritus, rash, erythematous rash, papular eruption, diplopia, ocular pain, ear pain, urinary incontinence, nocturnal enuresis, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, vascular edema, headache, dizziness, constipation, nausea, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, diarrhea, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms accompanying drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, memory impairment, forgetfulness, amnesic syndrome, memory disorders, confusion, hypotension, tachycardia, bradycardia, acute renal failure, hypotension, reflex tachycardia, shock state, non-cardiogenic pulmonary edema, elevated serum potassium and creatinine levels, symptoms of hypotension due to depletion of blood volume and sodium, vascular edema, thrombocytopenia, increased serum creatinine, acute renal failure, syncope, muscle cramps, gout, erectile dysfunction, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, appetite loss, abdominal distension, abnormal liver function tests, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that blocks light and at a temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain its effectiveness and prevents degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.